Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYK2 | P29597 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 5/20 | 0.39 |
| ▸ | EED | O75530 | 1/20 | 0.38 |
| ▸ | JAK1 | P23458 | 2/20 | 0.38 |
| ▸ | PRKCI | P41743 | 1/20 | 0.38 |
| ▸ | NT5E | P21589 | 1/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.37 |
| ▸ | RPS6KA5 | O75582 | 2/20 | 0.37 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.37 |
| ▸ | PKN2 | Q16513 | 2/20 | 0.37 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.37 |
| ▸ | CHUK | O15111 | 1/20 | 0.37 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.37 |
| ▸ | CDK1 | P06493 | 1/20 | 0.37 |
| ▸ | CDK2 | P24941 | 1/20 | 0.37 |
| ▸ | LTK | P29376 | 1/20 | 0.37 |
| ▸ | CDK8 | P49336 | 1/20 | 0.37 |
| ▸ | PRKX | P51817 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2856597 | 1.00 | TYK2 (0.44) | TYK2KDM4EL3MBTL1JAK2EED | |
| SCHEMBL4443812 | 1.00 | TYK2 (0.44) | TYK2KDM4EL3MBTL1JAK2EED | |
| Hydrochloric Acid SCHEMBL5956776 | 0.99 | TYK2 (0.43) | TYK2KDM4EL3MBTL1JAK2EED | |
| Hydrochloric Acid SCHEMBL5956945 | 0.99 | TYK2 (0.43) | TYK2KDM4EL3MBTL1JAK2EED | |
| SCHEMBL4445718 | 0.89 | TYK2 (0.46) | TYK2KDM4EL3MBTL1JAK2EED | |
| SCHEMBL4445713 | 0.89 | TYK2 (0.46) | TYK2KDM4EL3MBTL1JAK2EED | |
| SCHEMBL4446184 | 0.89 | TYK2 (0.46) | TYK2KDM4EL3MBTL1JAK2EED | |
| SCHEMBL2848053 | 0.87 | JAK2 (0.49) | TYK2JAK2JAK1PRKCINT5E | |
| SCHEMBL4444311 | 0.87 | JAK2 (0.49) | TYK2JAK2JAK1PRKCINT5E | |
| SCHEMBL2848056 | 0.87 | JAK2 (0.49) | TYK2JAK2JAK1PRKCINT5E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1270570-B1 | AMIDE COMPOUNDS AND USE THEREOF | MITSUBISHI PHARMA CORP (JP) | 2006-05-31 | — | — | EP | claimed |
| US-6933305-B2 | Amide compounds and use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2005-08-23 | — | — | US | claimed |
| US-20030158413-A1 | Amide compounds and use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2003-08-21 | — | — | US | claimed |
| EP-1270570-A1 | AMIDE COMPOUNDS AND USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2003-01-02 | — | — | EP | claimed |
| US-7696194-B2 | treating with fasudil hydrochloride; enzyme inhibitor of Rho kinase; promoting regeneration of an optic nerve cell | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2010-04-13 | — | — | US | disclosed |
| US-20090036465-A1 | COMBINATION THERAPY FOR PULMONARY ARTERIAL HYPERTENSION | UNITED THERAPEUTICS CORPORATION | 2009-02-05 | — | — | US | disclosed |
| US-7109208-B2 | Visual function disorder improving agents | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2006-09-19 | — | — | US | disclosed |
| US-20060148852-A1 | Visual function disorder improving agents | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2006-07-06 | — | — | US | disclosed |
| EP-1270570-B1 | AMIDE COMPOUNDS AND USE THEREOF | MITSUBISHI PHARMA CORP (JP) | 2006-05-31 | — | — | EP | disclosed |
| US-6933305-B2 | Amide compounds and use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2005-08-23 | — | — | US | disclosed |
| US-20040106646-A1 | Visual function disorder improving agents | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2004-06-03 | — | — | US | disclosed |
| EP-1378247-A1 | VISUAL FUNCTION IMPROVING AGENTS | Senju Pharmaceutical Co., Ltd. (JP) | 2004-01-07 | — | — | EP | disclosed |
| US-20030158413-A1 | Amide compounds and use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2003-08-21 | — | — | US | disclosed |
| EP-1270570-A1 | AMIDE COMPOUNDS AND USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2003-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030158413-A1 | Amide compounds and use thereof | ROCK2, ROCK1, RHOT2 | TYK2 354/4885KDM4E 1686/4885L3MBTL1 1645/4885 |
| US-20040106646-A1 | Visual function disorder improving agents | ARHGDIA, GAP43, RHOT2 | TYK2 4859/4885KDM4E 1199/4885L3MBTL1 3294/4885 |
| US-20090036465-A1 | COMBINATION THERAPY FOR PULMONARY ARTERIAL HYPERTENSION | ROCK1, ROCK2, RHOA | TYK2 1877/4885KDM4E 4466/4885L3MBTL1 4366/4885 |
| US-20060148852-A1 | Visual function disorder improving agents | GAP43, ARHGDIA, RHOT2 | TYK2 4877/4885KDM4E 1357/4885L3MBTL1 3360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.